



INSIDE VENTURE

50 Top Growth Companies Seeking Combined Total of Over \$1 Billion in Private Funding Utilize InsideVenture's New Financing Platform

InsideVenture's Debut Investor Conference to Feature Top pre-IPO Companies, March 25-26, Santa Barbara, Calif.

Menlo Park, Calif. – March 12, 2009 – InsideVenture, Inc. today announced that 50 companies have been selected to present their investment opportunities to long-term investors in one-on-one meetings over two days at the invitation-only conference. Presenting companies include biopharmaceuticals company AVEO Pharmaceuticals, clean technology company SolFocus, Inc., and high-tech storage technology company, Fusion-io. Each company will conduct 1:1 meetings with investors at InsideVenture's conference March 25-26 in Santa Barbara, California. InsideVenture's Selection Boards of Founders and Partners of many top venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant, selected these 50 top companies from over 170 nominations. Over 130 investors are represented in the selected companies.

“We are honored to support 50 of the world's top private companies in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara,” said Mona DeFrawi, Chief Executive Officer of InsideVenture.

“InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These are the companies that have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth.”

InsideVenture Investor Conference – March 25-26, Santa Barbara, Calif.

50 top late-stage private healthcare and technology companies seek to raise \$20-200M or establish relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, private equity funds and strategic corporate investors. Investors interested in attending the conference may apply for a trial membership in InsideVenture; the conference is exclusive to members and by invitation only. The theme of this year's conference is Investing in Innovation: Innovation in Investing. Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.

InsideVenture Conference & Membership Contact:
Benjamin Levy, Vice President

(650) 926-0661
blevy@insideventure.com



Market Segment: Biopharmaceuticals
Location: Cambridge, MA
Spokesperson: Tuan Ha-Ngoc, President and CEO
Contact: Sheryl Seapy, Pure Communications (949) 608-0841,
sheryl@purecommunicationsinc.com

“AVEO’s supportive and sophisticated investors have been crucial to our progress in discovering and developing cancer therapeutics. We view our membership in InsideVenture and our participation in the one-on-one meetings at the conference as a key step in educating institutional investors on the potential for AVEO to become a competitive and fully integrated biopharmaceutical company.” – Tuan Ha-Ngoc, President and CEO, AVEO Pharmaceuticals

About AVEO

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. The company’s lead product, AV-951, a novel, triple VEGF receptor inhibitor, is in a Phase 2 clinical trial in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at www.aveopharma.com.

Fusion-io



Market Segment: Solid State Technology
Location: Redwood Shore, CA
Spokesperson: David Bradford, Chief Executive Officer
Contact: Shannon Heward, Executive Assistant to Mr. Bradford, (801) 424-5518,
sheward@fusionio.com

"In almost an unprecedented economic environment InsideVenture represents a welcome shift in how outstanding growth-oriented companies can be exposed to some of the top financial institutions on planet earth." – David Bradford, CEO, Fusion-io

About Fusion-io

Fusion-io is a leading provider of enterprise solid-state technology and high-performance I/O solutions. The company's solid state storage technology closes the gap between processing power and storage needs delivering breakthrough performance at a fraction of the cost of traditional disk-based storage systems. The result is a world of possibilities for performance-starved applications. For more information, please visit www.fusionio.com.

SolFocus

SolFocus™

Innovation Inspired by Nature

Market Segment: CleanTechnology

Location: Mountain View, CA

Spokesperson: Mark Crowley, President and CEO, SolFocus, Inc.

Contact: Nancy Hartsoch, VP Marketing, (650) 623.7100, nancy_hartsoch@solfocus.com

"The state of the global economy highlights both the necessity for innovation in energy and innovation in the financial markets. The next generation of clean alternative energy companies will require the foresight of innovative investors like those who are members of InsideVenture." – Mark Crowley, President and CEO, SolFocus

About SolFocus

The SolFocus mission is to enable solar energy generation at a Levelized Cost of Energy (LCOE) competitive with traditional fossil fuel sources. To achieve this goal, SolFocus has developed leading concentrator photovoltaic (CPV) technology which combines high-efficiency solar cells (approaching 40%) and advanced optics to provide solar energy solutions which are scalable, dependable and capable of delivering on the promise of clean, low-cost, renewable energy. SolFocus is headquartered in Mountain View, California with European operations headquartered in Madrid, Spain, and manufacturing in Mesa, Arizona as well as with manufacturing partners in India and China.

www.solfocus.com

InsideVenture, Inc.



Market Segment: Financial Services

Location: Menlo Park, CA

Spokesperson: Mona DeFrawi, CEO

Contact: Matthew Stotts, TENOR, (415) 786-2231, matthew@tenorcom.com

About InsideVenture

InsideVenture is an industry sponsored financial marketing utility creating a direct private market platform for institutional and strategic investment in late-stage private companies. InsideVenture's exclusive vetting and membership requirements connect the best late-stage venture-backed companies with revered long-term institutional and strategic investors to facilitate late-stage transactions, IPO participation and aftermarket support. InsideVenture is supported by investment leaders like T. Rowe Price, Wasatch Advisors, SVB Financial Group, NYSE, Alexandria Equities, Intralinks Corporation, New Enterprise Associates, Domain Associates, DCM, Venrock Associates, Versant Ventures, Frazier Healthcare Ventures, Clarus Ventures, and Aisling Capital among others. InsideVenture is based in Menlo Park, California and on the web at www.insideventure.com